<DOC>
	<DOCNO>NCT01456663</DOCNO>
	<brief_summary>This study ass pharmacokinetics AFQ056 subject mild , moderate , severe hepatic impairment compare healthy control subject .</brief_summary>
	<brief_title>A Study Evaluate Pharmacokinetics AFQ056 Subjects With Hepatic Impairment Compared Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<criteria>Groups 1 , 2 , 3 4 ( subject ) Male female Caucasian subject Group 1 , 2 3 ( subject hepatic impairment ) Subjects must satisfy criterion hepatic impairment evidence ChildPugh score A , B C screen Group 4 ( healthy subject ) Each healthy subject must match age ( ±8 year ) , gender , weight ( ±15 % ) individual subject hepatic impairment group 1 , 2 3 . Groups 1 , 2 , 3 4 ( subject ) Use tobacco product 1 week prior cotinine screen assessment study completion . Group 1 , 2 3 ( subject hepatic impairment ) History drug alcohol abuse within 3 month prior screen History presence clinically significant disease major system organ class include ( limited ) cardiovascular , metabolic , renal , neurological psychiatric disease within 1 month prior study drug administration except hepatic impairment disease associate underlying condition . Any surgical medical condition hepatic impairment might significantly alter absorption , distribution , metabolism , excretion drug , may jeopardize safety study subject case participation study . History presence encephalopathy within 6 month prior screen ( except subject Groups 2 3 ) . Documented presence portosystemic shunt . Documented presence esophagus varix ( stage III IV ) . Group 4 ( healthy subject ) History presence clinically significant disease major system organ class include ( limited ) cardiovascular , metabolic , renal , neurological psychiatric disease . Any surgical medical condition might significantly alter absorption , distribution , metabolism , excretion drug , may jeopardize safety study subject case participation study . History drug alcohol abuse within 12 month prior screen , evidence abuse indicate laboratory assay conduct screen baseline . History presence hepatitis B C and/or positive Hepatitis B surface antigen ( HBsAg ) Hepatitis C test result screening . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>AFQ056</keyword>
	<keyword>Hepatic impairment</keyword>
	<keyword>Hepatic impair</keyword>
</DOC>